1. Home
  2. KRYS vs CYTK Comparison

KRYS vs CYTK Comparison

Compare KRYS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krystal Biotech Inc.

KRYS

Krystal Biotech Inc.

N/A

Current Price

$305.25

Market Cap

9.2B

Sector

Health Care

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$56.14

Market Cap

7.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRYS
CYTK
Founded
2015
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2B
7.8B
IPO Year
2017
2004

Fundamental Metrics

Financial Performance
Metric
KRYS
CYTK
Price
$305.25
$56.14
Analyst Decision
Strong Buy
Buy
Analyst Count
12
22
Target Price
★ $388.22
$109.42
AVG Volume (30 Days)
296.5K
★ 1.9M
Earning Date
11-02-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 128.00
N/A
EPS
★ 5.66
N/A
Revenue
★ $389,130,000.00
$13,368,000.00
Revenue This Year
$27.84
$87.17
Revenue Next Year
$27.62
$170.90
P/E Ratio
$54.71
★ N/A
Revenue Growth
★ 33.94
N/A
52 Week Low
$198.02
$53.58
52 Week High
$382.54
$88.31

Technical Indicators

Market Signals
Indicator
KRYS
CYTK
Relative Strength Index (RSI) 43.87 38.83
Support Level $284.16 N/A
Resistance Level $317.53 $66.62
Average True Range (ATR) 11.47 2.68
MACD 0.01 -0.27
Stochastic Oscillator 49.77 25.69

Price Performance

Historical Comparison
KRYS
CYTK

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: